One Molecule at a Time: The Digest’s 2018 Multi-Slide Guide to Amyris

For many people, a key question in the advanced bioeconomy continues to be: “what is Amyris becoming, and when, and where and how?”

Becoming a global leader in the health and beauty market, and self-funding operations in 2018 with at least $10 million in EBITDA this year — those are the targets appearing out of Emeryville now.

Amyris’ President of R&D, Joel Cherry, gave this presentations on Amyris technology and the outlook from 2018 and beyond in recent weeks — an illuminating overview of Amyris’ promise and progress on multiple fronts.